Demetrovics Zsolt, Farkas Judit, Csorba József, Németh Attila, Mervó Barbara, Szemelyácz János, Fleischmann Enikö, Kassai-Farkas Akos, Petke Zsolt, Oroján Tibor, Rózsa Sándor, Rigó Péter, Funk Sándor, Kapitány Máté, Kollár Anna, Rácz József
Eötvös Loránd University, Institutional Group on Addiction Research, Budapest, Hungary.
Neuropsychopharmacol Hung. 2009 Dec;11(4):249-57.
Suboxone (Buprenorphine/naloxone) is a novel drug used in opiate substitution therapy. In Hungary, it was introduced in November 2007. Suboxone is a product for sublingual administration containing the partial mu-receptor agonist buprenorphine and antagonist naloxone in a 4:1 ratio.
Objectives of our study were to monitor and evaluate the effects of Suboxone treatment.
6 outpatient centers participated in the study, 3 from Budapest and 3 from smaller cities in Hungary. At these centers, all patients entering Suboxone maintenance therapy between November 2007 and March 2008, altogether 80 persons (55 males, 35 females, mean age = 30.2 years, SD=5.48) were included in the study sample. During the 6-month period of treatment, data were collected 4 times; when entering treatment, 1 month, 3 months, and 6 months after entering treatment. Applied measures were the Addiction Severity Index, SCID-I, SCID-II, Hamilton Depression Scale, Hamilton Anxiety Scale, STAI-S State Anxiety Inventory, Beck Depression Inventory, Heroin Craving Questionnaire, WHO Well-being Inventory, Perceived Stress Scale, ADHD retrospective questionnaire, TCI short version, and Ways of Coping questionnaire.
Nearly fourth of the altogether 80 heroin dependent patients (18 persons, 22.5%) dropped out of treatment during the first month (the majority, 12 persons [15%] during the first week) or chose methadone substitution instead. Following this period however, dropout rate decreased and the six-month treatment period was completed by 32 patients (40%). During the first month of treatment significant positive changes were experienced in all studied psychological and behavioral dimensions that proved to be stabile throughout the studied period.
According to the early experience with Suboxone treatment, it is a well tolerable and successfully applicable drug in the substitution therapy of opiate addicts. A critical phase seems to be the first one or two weeks of treatment. Dropout rate is high during this early period, while after a successful conversion clients presumably remain in therapy for a long period. At the beginning of administration special emphasis must be put on informing patients, especially concerning withdrawal symptoms that might be present during the first week, which highly contributes to better retention in treatment.
丁丙诺啡/纳洛酮(商品名:舒倍生)是一种用于阿片类药物替代疗法的新型药物。2007年11月在匈牙利投入使用。舒倍生是一种舌下给药产品,含有4:1比例的μ-受体部分激动剂丁丙诺啡和拮抗剂纳洛酮。
本研究的目的是监测和评估舒倍生治疗的效果。
6个门诊中心参与了该研究,其中3个来自布达佩斯,3个来自匈牙利的小城市。在这些中心,2007年11月至2008年3月期间所有开始舒倍生维持治疗的患者,共80人(55名男性,35名女性,平均年龄 = 30.2岁,标准差 = 5.48)被纳入研究样本。在6个月的治疗期间,收集了4次数据;分别在开始治疗时、治疗1个月、3个月和6个月时。应用的测量工具包括成瘾严重程度指数、SCID-I、SCID-II、汉密尔顿抑郁量表、汉密尔顿焦虑量表、状态焦虑问卷、贝克抑郁量表、海洛因渴求问卷、世界卫生组织幸福量表、感知压力量表、注意力缺陷多动障碍回顾问卷、TCI简版和应对方式问卷。
在总共80名海洛因依赖患者中,近四分之一(18人,22.5%)在第一个月退出治疗(大多数,12人[15%]在第一周)或选择了美沙酮替代治疗。然而在此之后,退出率下降,32名患者(40%)完成了为期6个月的治疗。在治疗的第一个月,所有研究的心理和行为维度都出现了显著的积极变化,并且在整个研究期间保持稳定。
根据舒倍生治疗的早期经验,它在阿片类成瘾者的替代治疗中是一种耐受性良好且成功适用的药物。关键阶段似乎是治疗的第一或两周。在此早期阶段退出率很高,而成功转换后患者可能会长期接受治疗。在开始给药时,必须特别强调告知患者,尤其是关于第一周可能出现的戒断症状,这对提高治疗的保留率有很大帮助。